Market Performance - The Tel Aviv Stock Exchange experienced a significant rise, with the Tel Aviv 35 Index increasing by 2.70% to 3,116.75 points, and the Tel Aviv 125 Index rising by 3% to 3,161.33 points, following positive news regarding a potential deal to return hostages and end the Gaza conflict [1] - The All Bond corporate bond index rose by 0.19% to 413.19 points, with total turnover in equities reaching NIS 1.91 billion and NIS 4.08 billion in bonds [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.658% higher at NIS 3.366/$, while the shekel-euro rate increased by 0.107% to NIS 3.929/€ [2] Leading Companies - Bank Leumi led the market with a rise of 4.59%, followed by Bank Hapoalim at 4.48%, Mizrahi Tefahot Bank at 4.79%, and Israel Discount Bank at 5.53% [2] - Phoenix Financial saw the largest increase on the Tel Aviv 35 Index, rising by 9.78%, while Menora Mivtachim rose by 6.21%, Harel Finance and Investments by 8.13%, and Clal Insurance Enterprise Holdings by 6.56% [3] Declining Companies - Nice experienced the largest decline on the Tel Aviv 35 Index, falling by 2.43%, followed by Nova Ltd. at 1.61% and Teva Pharmaceutical Industries at 2.02% [4]

Market Performance - The Tel Aviv Stock Exchange experienced a decline, with the Tel Aviv 35 Index falling 0.13% to 3,054.16 points, the Tel Aviv 125 Index down 0.39% to 3,102.85 points, and the BlueTech Global Index decreasing by 1.05% to 554.12 points [1] - The All Bond corporate bond index also fell by 0.03% to 411.25 points, with total turnover in equities reaching NIS 3.69 billion and NIS 4.72 billion in bonds [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.06% higher at NIS 3.343/$, while the shekel-euro rate increased by 0.53% to NIS 3.948/€ [2] Notable Stock Movements - Bank Hapoalim led the market with a rise of 0.49%, while Bank Leumi increased by 0.73% [2] - NewMed Energy saw the largest gain on the Tel Aviv 25 Index, rising 2.92%, followed by Energean plc at 2.72%, Elbit Systems Ltd. at 1.99%, and Nova Ltd. at 1.64% [3] - Teva Pharmaceutical Industries Ltd. experienced the largest decline on the Tel Aviv 35 Index, falling by 3.6%, with Camtek down 1.32% and Azrieli Group down 0.81% [3] Additional Company Movements - Mizrahi Tefahot Bank fell by 1.51%, and Israel Discount Bank decreased by 1.29% [4] - NextVision Stabilized Systems dropped 4.49% after announcing a $400 million capital raise [4]

Market Overview - The Tel Aviv Stock Exchange experienced a decline following Prime Minister Benjamin Netanyahu's comments on Israel's need for self-sufficiency, which overshadowed previous gains. The Tel Aviv 35 Index decreased by 0.27% to 3,058.22 points, the Tel Aviv 125 Index fell by 0.55% to 3,114.92 points, and the BlueTech Global Index dropped by 0.50% to 560.02 points. The All Bond corporate bond index also fell by 0.12% to 411.38 points. Total turnover in equities was NIS 2.80 billion and in bonds was NIS 3.83 billion [1]. Currency Exchange Rates - In the foreign exchange market, the shekel-dollar rate increased by 0.421% to NIS 3.341/$, while the shekel-euro rate rose by 0.522% to NIS 3.927/€ [2]. Company Performances - Bank Hapoalim led the market with a slight increase of 0.05% and the highest trading turnover. Mizrahi Tefahot Bank rose by 0.62%. Nova Ltd. recorded the largest gain on the Tel Aviv 35 Index, rising by 2.61%. Camtek increased by 1.44%, Bezeq Israel Telecommunications Company rose by 1.16%, and Ormat Technologies saw a rise of 1.56% [3]. Declines in Company Stocks - Clal Insurance Enterprise Holdings experienced the largest decline on the Tel Aviv 35 Index, falling by 3.97%. Phoenix Financial dropped by 3.22%. Other notable declines included Teva Pharmaceutical Industries, which fell by 1.68%, Elbit Systems decreased by 0.54%, and Delek Group saw a decline of 2.09% [4].

Core Insights - Alvotech, a global biotech company, specializes in the development and manufacture of biosimilar medicines and will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025 [1][2] Company Overview - Alvotech was founded by Robert Wessman and aims to be a leader in the biosimilar market by providing high-quality, cost-effective products and services through a fully integrated approach [3] - The company has launched two biosimilars and has a development pipeline targeting treatments for autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] - Alvotech has established a network of strategic commercial partnerships across various regions, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3]

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline that includes candidates for treating autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the Goldman Sachs 46th Global Healthcare Conference in Miami, Florida, from June 9-11, 2025 [1] - Dr. Balaji Prasad, Chief Strategy Officer, will engage in a fireside chat on June 11, 2025, at 8:00 am EDT [1][2]

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the Goldman Sachs 46th Global Healthcare Conference in Miami, Florida, from June 9-11, 2025 [1] - Dr. Balaji Prasad, Chief Strategy Officer, will engage in a fireside chat on June 11, 2025, at 8:00 am EDT [1][2]

Group 1: Company Overview - Alvotech is a biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services [3] - Alvotech has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [3] - The current development pipeline includes nine disclosed biosimilar candidates targeting various diseases, including autoimmune disorders and cancer [3] Group 2: Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise [3] - Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd., among others, covering various territories [3] - Each partnership is tailored to specific products and regions, enhancing Alvotech's market presence [3] Group 3: Liquidity Provider Agreement - Alvotech has entered into an agreement with DNB Carnegie Investment Bank AB for liquidity provider services for its Swedish Depository Receipts (SDRs) [1] - DNB Carnegie will continuously quote prices for Alvotech's SDRs to ensure liquidity and reduce the spread between buying and selling prices [2] - The liquidity provider arrangement is set to commence on May 20, 2025 [2]

Core Viewpoint - Alvotech, a global biotech company focused on biosimilar medicines, successfully completed an oversubscribed offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm, which is expected to enhance its market presence and access to capital [2][5][8]. Offering Details - The offering attracted strong interest, resulting in over 3,000 new shareholders and was multiple times oversubscribed [2][8]. - The final price per SDR was set at SEK 87.51, reflecting a 10% discount from the volume-weighted average price of the ordinary shares during the application period [8]. - The gross proceeds from the offering amounted to approximately SEK 39 million [8]. Strategic Expansion - Alvotech aims to expand its R&D capabilities, having recently acquired Xbrane Biopharma AB's R&D operations in Sweden, which will enhance its scientific and innovation capabilities [4]. - The integration of Xbrane's workforce is expected to strengthen Alvotech's presence in the Swedish life-science sector and support its growth trajectory [4]. Market Positioning - The listing on Nasdaq Stockholm is anticipated to improve Alvotech's recognition in Nordic and European markets, attracting a broader base of institutional and retail investors [5]. - There is strong investor demand for opportunities in European biotech, biopharma, and biosimilar stocks among Nordic and international institutional investors [5]. Trading Information - Trading of the SDRs on Nasdaq Stockholm is set to commence on May 19, 2025, under the ticker symbol "ALVO SDB" [8]. - A free conversion period for existing shareholders to convert their shares into SDRs will be offered for one year from the first trading day [7].

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach and broad in-house capabilities [3] - Alvotech has launched two biosimilars and has a development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise in various markets, including the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [3] - Notable commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd., and Dr. Reddy's, among others, each covering unique products and territories [3] Upcoming Events - Alvotech will participate in the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada, from May 13-15, 2025, hosting one-on-one meetings and a fireside chat on May 14, 2025 [1] - A live audio webcast of the fireside chat will be available to the public, with a recording accessible for 90 days post-event [2]

Core Viewpoint - Alvotech has announced the acquisition of Xbrane Biopharma AB's R&D operations and a biosimilar candidate, XB003, which will enhance its development capabilities and establish a presence in the Swedish life science sector [1][3][6] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, with a goal to be a leader in the biosimilar space by providing high-quality, cost-effective products [4][7] - The company has invested approximately $1.9 billion since 2013 in a biosimilars R&D and manufacturing platform and has established partnerships with 19 leading companies across over 90 global markets [4][7] Acquisition Details - The acquisition includes Xbrane's R&D operations located at the Karolinska Institute in Sweden and the biosimilar candidate XB003, which references Cimzia® [1][6] - The purchase price for the acquisition is approximately SEK 275 million (around USD 27 million), consisting of SEK 102.2 million in cash and SEK 172.8 million in assumed debt and accounts payable [6] - The closing of the acquisition is expected in April 2025, pending approvals from relevant authorities and Xbrane's shareholders [6] Strategic Implications - This acquisition will allow Alvotech to expand its development capacity and enhance patient access to quality biologics through its commercial network of 19 partners [3][6] - Alvotech aims to attract new talent and foster scientific collaboration in the Swedish life science sector, which is comparable to the U.S. in this field [3][6] - Xbrane will retain over 75% of its addressable market, focusing on the commercialization of its remaining pre-clinical assets, including Ximluci and Xdivane [3][6]